GLAXF News and Press, GlaxoSmithKline Plc From 05/01/23

2023-05-01 23:53:08 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Arrowhead Pharmaceuticals and Meta propelled my portfolio again to all-time highs and mar...

2023-04-26 11:46:10 ET GSK plc (GSK) Q1 2023 Earnings Conference Call April 26, 2023, 07:00 AM ET Company Participants Nick Stone - SVP, Head, IR Emma Walmsley - CEO & Director Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer ...

2023-04-25 14:16:04 ET Summary Positive preliminary results were released by CureVac N.V. from both the flu and Covid-19 vaccine programs back in January of 2023. GlaxoSmithKline is an established partner to advance both the Covid-19 and flu prophylactic vaccine programs. The ...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-10 08:26:10 ET Summary GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. Bristol-Myers Squibb's total debt was about $40.8 billion at the end of 2022, down $4.78 billion from the previous year, thanks to the successful integration of Celgene...

2023-04-03 04:12:14 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Bitcoin, AMD, and Meta propelled my portfolio to all-time highs and market-beating return...

2023-03-06 23:01:05 ET Summary Kahn Brothers’ 13F portfolio value increased from ~$642M to ~$760M this quarter. Most of the stakes saw minor adjustments during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~49% o...

2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...